Based on a vision that C6 inhibition is safe and effective to modify neurodegeneration and an IP estate securing the mechanism, the antibody and the LNA program; Complement Pharma has developed an antibody that binds to C6 in circulation to inhibit C6 up and into the CNS and is developing a value adding LNA program.